Percutaneous coronary intervention for patients with type 2 diabetes mellitus: risks and novel way to manage
https://doi.org/10.14341/DM9827
Abstract
The article is a literature review devoted to issues of planned percutaneous coronary intervention for patients with type 2 diabetes mellitus. Pathogenetic base of poor prognosis and new ways to pharmacological risk correction are described.
The article highlights the trends in the incidence of carbohydrate metabolism disorders, their role in the development of complications of myocardial revascularization. The results of studies comparing different tactics of revascularization and their results in patients with different status of carbohydrate metabolism are presented.
The article discusses the methods of risk management within percutaneous coronary revascularization, the role of glycemic metabolism in the risk of an poor prognosis of myocardial revascularization, describes the results of clinical trials of new drugs that can have a positive effect on the prognosis of revascularization in patients with carbohydrate metabolism disorders.
About the Authors
Anastasia M. KocherginaResearch Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Russian Federation
MD, PhD
Alina A. Khorlampenko
Kemerovo State Medical University
Russian Federation
postgraduate student of department of cardiology and cardiovascular surgery
References
1. WHO Mortality Database [Internet]. WHO; 2018 [updated: 2018 May 8]. Available from: http://apps.who.int/healthinfo/statistics/mortality/whodpms.
2. Сайгитов Р.Т., Чулок А.А. Сердечно-сосудистые заболевания в контексте социально-экономических приоритетов долгосрочного развития России // Вестник Российской академии медицинских наук. – 2015. – Т.70. – №3. – С. 286−299. [Saygitov RT, Chulok AA. Cardiovascular diseases in the context of Russia’s long-term socio-economic development priorities. Annals of the Russian Academy of Medical Sciences. 2015;70(3):286−299. (In Russ.)] doi: https://doi.org/10.15690/vramn.v70i3.1324
3. Аметов А.С., Курочкин И.О., Зубков А.А. Сахарный диабет и сердечно-сосудистые заболевания // Русский медицинский журнал. – 2014. – Т.22. – №13. – С.943−958. [Ametov AS, Kurochkin IO, Zubkov AA. Diabetes mellitus and cardiovascular diseases. Russkii Meditsinskii Zhurnal. 2014;22(13):943−958. (In Russ.)]
4. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–149. doi: https://doi.org/10.1016/j.diabres.2013.11.002
5. Дедов И.И., Шестакова М.В., Сунцов Ю.И., и др. Результаты реализации подпрограммы «Сахарный диабет» федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями (2007–2012 годы)» // Сахарный диабет. – 2013. – Т.16. – №2S. – С. 1–48. [Dedov II, Shestakova MV, Suntsov YI, et al. Federal targeted programme ‘Prevention and management of socially significant diseases (2007−2012): results of the ‘Diabetes mellitus’ sub-programme. Diabetes mellitus. 2013;16(2S):1–48. (In Russ.)] doi: https://doi.org/10.14341/2072-0351-3879
6. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION) // Сахарный диабет. – 2016. – Т.19. – №2. – С. 104–112. [Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104–112. (In Russ.)] doi: https://doi.org/10.14341/DM2004116-17
7. Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and developed in collaboration with the European association for the study of diabetes (EASD). Eur Heart J. 2013;34(39):3035−3087. doi: https://doi.org/10.1093/eurheartj/eht108
8. Игнатова Ю.С., Каретникова В.Н., Кочергина А.М., и др. Диагностика и коррекция нарушений углеводного обмена перед плановым чрескожным коронарным вмешательством в условиях реальной клинической практики // Сердце: журнал для практикующих врачей. – 2017. – Т.16. – №4. – С. 253–259. [Ignatova YS, Karetnikova VN, Kochergina AM, et al. Diagnosis and correction of carbohydrate metabolism disorders before elective transcutaneous coronary intervention in conditions of real-life clinical practice. Russian Heart Journal. 2017;16(4):253–259. (In Russ.)] doi: https://doi.org/10.18087/rhj. 2017.4.2365
9. Кочергина А.М., Игнатова Ю.С., Каретникова В.Н., и др. Выявление нарушений углеводного обмена перед плановым чрескожным коронарным вмешательством. / Сборник тезисов Республиканской научно-практической конференции «Метаболический синдром и другие категории дисметаболизма»; Ташкент, 13 апреля 2017. – Ташкент: ООО «Polisar-tex»; 2017. – С. 79. [Kochergina AM, Ignatova YS, Karetnikova VN, et al. Vyyavlenie narushenii uglevodnogo obmena pered planovym chreskozhnym koronarnym vmeshatelstvom. In: Proceedings of the Republican scientific-practical conference "Metabolic syndrome and other categories of dysmetabolism"; Tashkent, 13 April 2017. Tashkent: Ltd «Polisar-tex»; 2017. P. 79. (In Russ.)]
10. Balakrishnan R, Berger JS, Tully L, et al. Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention. Diabetes Metab Res Rev. 2015;31(6):603–609. doi: https://doi.org/10.1002/dmrr.2646
11. Безденежных Н.А., Сумин А.Н., Барбараш О.Л. Пациент с сахарным диабетом и реваскуляризация миокарда с позиций доказательной медицины: взгляд кардиолога. Часть 1 // Российский кардиологический журнал. – 2017.— Т.4. – №144. – С. 105–113. [Bezdenezhnykh NA, Sumin AN, Barbarash OL. Patients with diabetes and myocardial revascularization from evidence-based medicine positions: cardiologist’s opinion. Part 1. Russ J Cardiol. 2017;4(144):105–113. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2017-4-105-113
12. Davidson MH. Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. Am J Cardiol. 2012;110(9 Suppl):43–49. doi: https://doi.org/10.1016/j.amjcard.2012.08.033
13. Мичурова М.С., Кононенко И.В., Смирнова О.М., и др. Влияние компенсации углеводного обмена и вида гипогликемизирующей терапии на исходы эндоваскулярных вмешательств у больных сахарным диабетом 2 типа // Сахарный диабет. – 2014. – №1. – С. 34–40. [Michurova MS, Kononenko IV, Smirnova OM, et al. Effects of diabetes compensation by various classes of antihyperglycemic agents on endovascular intervention outcomes in patients with type 2 diabetes mellitus. Diabetes mellitus. 2014;(1):34–40. (In Russ.)] doi: https://doi.org/10.14341/DM2014134-40
14. Кошкарбаева А.К., Афанасьева С.Н. Инсулинорезистентность как ведущий фактор риска ишемической болезни сердца при сахарном диабете 2 типа // Архивъ внутренней медицины. – 2013. – №13. – С. 35–39. [Koshkarbaeva AK, Afanaseva SN. Insulinorezistentnost' kak vedushchii faktor riska ishemicheskoi bolezni serdca pri saharnom diabete 2 tipa. Arhiv vnutrennei mediciny. 2013;(13):35−39. (In Russ.)] doi: https://doi.org/10.20514/2226-6704-2013-0-5-35-39
15. New SE, Goettsch C, Aikawa M, et al. Macrophage-derived matrix vesicles: an alternative novel mechanism for microcalcification in atherosclerotic plaques. Circ Res. 2013;113(1):72–77. doi: https://doi.org/10.1161/CIRCRESAHA.113.301036
16. Heath JM, Sun Y, Yuan K, et al. N-acetylglucosamine induces vascular calcification in diabetes mellitus. Circ Res. 2014;114(7):1094–1102. doi: https://doi.org/10.1161/CIRCRESAHA.114.302968
17. Шафранская К.С., Зыков М.В., Быкова И.С., и др. Влияние почечной дисфункции на ранние и отдаленные результаты коронарного шунтирования // Комплексные проблемы сердечно-сосудистых заболеваний. – 2017. – №1. – С. 27−36. [Shafranskaya KS, Zykov MV, Bykova IS, et al. Impact of renal dysfucntion on early and long term outcomes after coronary artery bypass grafting. Complex Issues of Cardiovascular Diseases. 2017;(1):27–36. (In Russ.)] doi: https://doi.org/10.17802/2306-1278-2017-1-27-36
18. Nichols GA, Déruaz-Luyet A, Hauske SJ, Brodovicz KG. The association between estimated glomerular filtration rate, albuminuria, and risk of cardiovascular hospitalizations and all-cause mortality among patients with type 2 diabetes. J Diabetes Complications. 2018;32(3):291−297. doi: https://doi.org/10.1016/j.jdiacomp.2017.12.003
19. Murata N, Kaneko H, Yajima J. The prognostic impact of worsening renal function in Japanese patients undergoing percutaneous coronary intervention with acute coronary syndrome. J Cardiol. 2015;66(4):326−332. doi: https://doi.org/10.1016/j.jjcc.2014.12.005
20. Евсеева М.В., Каретникова В.Н., Барбараш О.Л. Нарушение функции почек у больных инфарктом миокарда с сопутствующим сахарным диабетом 2-го типа // Терапевтический архив. – 2015. –Т.87. – №1. – С. 105−108. [Evseeva MV, Karetnikova VN, Barbarash OL. Renal dysfunction in patients with myocardial infarction concurrent with type 2 diabetes mellitus. Ther Arch. 2015;87(1):105–108. (In Russ.)] doi: https://doi.org/10.17116/terarkh2015871105-108.
21. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998;32(7):1866–1873. doi: https://doi.org/10.1016/S0735-1097(98)00467-7
22. Farkouh ME, Domanski M, Sleeper LA, et al.; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375–2384. doi: https://doi.org/10.1056/NEJMoa1211585
23. Kappetein AP, Head SJ, Morice MC, et al.; SYNTAX Investigators. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 2013;43(5):1006–1013. doi: https://doi.org/10.1093/ejcts/ezt017
24. Tomai F, Reimers B, De Luca L, et al. Head-to-head comparison of sirolimus and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions. Diabetes Care. 2008;31(1):15–19. doi: https://doi.org/10.2337/dc07-1377
25. Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus-versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial. JACC Cardiovasc Interv. 2011;4(3):310–316. doi: https://doi.org/10.1016/j.jcin.2010.12.006
26. Planer D, Smits PC, Kereiakes DJ. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (a clinical evaluation of the XIENCE V everolimus eluting coronary stent system) and COMPARE (a trial of everolimus-eluting stents and paclitaxel-eluting stents for coronary revascularization in daily practice) trials. JACC Cardiovasc Interv. 2011;4(10):1104−1115. doi: https://doi.org/10.1016/j.jcin.2011.06.018
27. Volz S, Angeras O, Odenstedt J, et al. Sustained risk of stent thrombosis and restenosis in first generation drug-eluting stents after one decade of follow-up: a report from the Swedish coronary angiography and angioplasty registry (SCAAR). Catheter Cardiovasc Interv. 2018;92(6):E403−E409. doi: 10.1002/ccd.27655
28. Claessen BE, Henriques JP, Vendrik J, et al. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: insights from the randomized DARE trial. Catheter Cardiovasc Interv. 2019;93(2):216−221. doi: https://doi.org/10.1002/ccd.27814
29. Masiero G, Mojoli M, Ueshima D, Tarantini G. Current concepts on coronary revascularization using BRS in patients with diabetes and small vessels disease. J Thorac Dis. 2017;9(Suppl 9):S940–S949. doi: https://doi.org/10.21037/jtd.2017.06.36
30. Kereiakes DJ, Ellis SG, Kimura T, et al. Efficacy and safety of the absorb everolimus-eluting bioresorbable scaffold for treatment of patients with diabetes mellitus: results of the absorb diabetic substudy. JACC Cardiovasc Interv. 2017;10(1):42−49. doi: https://doi.org/10.1016/j.jcin.2016.10.019
31. Sousa-Uva M, Neuman FJ, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 2019;55(1):4−90. doi: https://doi.org/10.1093/ejcts/ezy289
32. Мельникова О.Г. Британское проспективное исследование сахарного диабета (UKPDS) – результаты 30-летнего наблюдения больных сахарным диабетом 2 типа // Сахарный диабет. – 2008. – №4. – С. 91–92. [Melnikova OG. Britanskoe prospektivnoe issledovanie saharnogo diabeta UKPDS – rezultaty 30-letnego nablyudeniya bolnyh saharnym diabetom 2 tipa. Diabetes mellitus. 2008;(4):91–92. (In Russ.)] doi: https://doi.org/10.14341/2072-0351-5599
33. Федорова О.С. Диабетическая макроангиопатия и самоконтроль гликемии // Медицинский совет. – 2014. – №7. – С. 30–33. [Fedorova OS. Diabetic macroangiopathy and self-monitoring of glucose. Meditsinsky sovet. 2014;(7):30−33. (In Russ.)] doi: https://doi.org/10.21518/2079-701X-2014-7-30-33
34. Davis SN, Duckworth W, Emanuele N, et al. Effects of severe hypoglycemia on cardiovascular outcomes and death in the veterans affairs diabetes trial. Diabetes Care. 2019;42(1):157−163. doi: https://doi.org/10.2337/dc18-1144
35. Ueda H, Mitsusada N, Harimoto K, et al. Glycosylated hemoglobin is a predictor of major adverse cardiac events after drug-eluting stent implantation in patients with diabetes mellitus. Cardiology. 2010;116(1):51–57. doi: https://doi.org/10.1159/000314331
36. Lemesle G, Bonello L, de Labriolle A, et al. Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation. Am J Cardiol. 2009;104(1):41–45. doi: https://doi.org/10.1016/j.amjcard.2009.02.060
37. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 8-й выпуск // Сахарный диабет. – 2017. – Т.20. – №1S. – C. 1−121. [Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. Diabetes mellitus. 2017;20(1S):1−121. (In Russ.)] doi: https://doi.org/10.14341/DM20171S8
38. Kassaian SE, Goodarzynejad H, Boroumand MA, et al. Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc Diabetol. 2012;11:82. doi: https://doi.org/10.1186/1475-2840-11-82
39. Parrinello CM, Selvin E. Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. Curr Diab Rep. 2014;14(11):548. doi: https://doi.org/10.1007/s11892-014-0548-3
40. Kuroda M, Shinke T, Sakaguchi K, et al. Effect of daily glucose fluctuation on coronary plaque vulnerability in patients pre-treated with lipid-lowering therapy: a prospective observational study. JACC Cardiovasc Interv. 2015;8(6):800–811. doi: https://doi.org/10.1016/j.jcin.2014.11.025
41. Bundhun PK, Li N, Chen MH. Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis. Cardiovasc Diabetol. 2015;14:135. doi: https://doi.org/10.1186/s12933-015-0300-6
42. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410−1418. doi: https://doi.org/10.1056/NEJMoa1003795
43. U.S. Food and Drug Administration. Diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. Guidance for Industry, 2008 [updated: 2018 September 19]. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
44. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2018;41(12):2669−2701. doi: https://doi.org/10.2337/dci18-0033
45. Zinman B, Christoph W, John ML, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: https://doi.org/10.1056/NEJMoa1504720
46. Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396–3404. doi: https://doi.org/10.2337/dc12-2673
47. Корбут А.И., Климонтов В.В. Эмпаглифлозин: новая стратегия нефропротекции при сахарном диабете // Сахарный диабет. – 2017. – Т.20. – №1. – С. 75–84. [Korbut AI, Klimontov VV. Empagliflozin: a new strategy for nephroprotection in diabetes. Diabetes Mellitus. 2017;20(1):75−84. (In Russ.)] doi: https://doi.org/10.14341/DM8005
48. Zhang XL, Zhu QQ, Chen YH, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. 2018;7(2):pii: e007165. doi: https://doi.org/10.1161/JAHA.117.007165
49. Yaribeygi H, Butler AE, Atkin SL, et al. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways. J Cell Physiol. 2018;234(1):223−230. doi: https://doi.org/10.1002/jcp.26851
50. Недогода С.В. Снижение сердечно-сосудистого риска при сахарном диабете 2 типа на фоне лечения лираглутидом и его плейотропный эффект – мандат для кардиолога и терапевта // Российский кардиологический журнал. – 2018. – Т.23. – №4. – С. 89−92. [Nedogoda SV. Liraglutide pleiotropic effect in cardiovascular risk reduction in type 2 diabetes – a mandate for cardiologist and internist. Russ J Cardiol. 2018;23(4):89−92. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2018-4-89-92
Supplementary files
Review
For citations:
Kochergina A.M., Khorlampenko A.A. Percutaneous coronary intervention for patients with type 2 diabetes mellitus: risks and novel way to manage. Diabetes mellitus. 2019;22(2):151-158. (In Russ.) https://doi.org/10.14341/DM9827
Views:
1777
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
